PMID- 21115427
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20211203
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 10 Suppl 3
DP  - 2010 Nov
TI  - Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current 
      status and future directions.
PG  - S86-95
LID - 10.3816/CBC.2010.s.017 [doi]
AB  - The phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin 
      (mTOR) pathway regulates a broad spectrum of physiologic and pathologic 
      processes. In breast cancer mutation, amplification, deletion, methylation, and 
      posttranslational modifications lead to significant dysregulation of this pathway 
      leading to more aggressive and potentially drug-resistant disease. Multiple novel 
      agents, targeting different nodes within the pathway are currently under 
      development by both commercial and academic partners. The key to the successful 
      validation of these markers is selection of the appropriate patient groups using 
      biomarkers. This article reviews current progress in this area, highlighting the 
      key molecular alterations described in genes within the PI3K/Akt/mTOR pathway 
      that may have an effect on response to current and future therapeutic 
      interventions. Herein, gaps in current knowledge are highlighted and suggestions 
      for future research directions given that may facilitate biomarker development in 
      partnership with current drug development.
FAU - Bartlett, John M S
AU  - Bartlett JM
AD  - Endocrine Cancer Group and Edinburgh Breakthrough Breast Cancer Laboratory, 
      Edinburgh University,Western General Hospital, Crewe Road South, Edinburgh, UK. 
      john.bartlett@ed.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Biomarkers, Tumor/*antagonists & inhibitors/genetics
MH  - Breast Neoplasms/*drug therapy/enzymology
MH  - Female
MH  - Forecasting
MH  - Humans
MH  - Molecular Targeted Therapy/methods
MH  - Mutation/genetics
MH  - *Patient Selection
MH  - Phosphatidylinositol 3-Kinases/genetics
MH  - *Phosphoinositide-3 Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-akt/*antagonists & inhibitors/genetics
MH  - Signal Transduction/genetics
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/genetics
EDAT- 2010/12/01 06:00
MHDA- 2011/08/04 06:00
CRDT- 2010/12/01 06:00
PHST- 2010/12/01 06:00 [entrez]
PHST- 2010/12/01 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
AID - N367051602716271 [pii]
AID - 10.3816/CBC.2010.s.017 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2010 Nov;10 Suppl 3:S86-95. doi: 10.3816/CBC.2010.s.017.